Orchid Pharma is currently trading at Rs. 24.25, up by 2.80 points or 13.05% from its previous closing of Rs. 21.45 on the BSE.
The scrip opened at Rs. 22.90 and has touched a high and low of Rs. 25.30 and Rs. 22.35 respectively. So far 1963114 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 45.85 on 28-Sep-2016 and a 52 week low of Rs. 16.70 on 15-Sep-2017.
Last one week high and low of the scrip stood at Rs. 25.30 and Rs. 17.30 respectively. The current market cap of the company is Rs. 212.62 crore.
The promoters holding in the company stood at 26.68%, while Institutions and Non-Institutions held 5.05% and 68.27% respectively.
Orchid Pharma has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) based on the successful inspection of the Active Pharmaceutical Ingredients (API) manufacturing facility located at SIDCO Industrial Estate, Alathur, Kanchipuram District, Tamil Nadu, India. This facility was inspected by US FDA in May 2017.
Orchid Pharma is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients and finished dosage forms. It is also engaged in research of new drugs.
